

PTO-1449 REPRODUCED

MAIL DATE CANCELLED

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 5, 2001

(Use several sheets if necessary)

APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642

JUL 11 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIA TE
KA	AA	4,603,106	07/29/86	Cerami et al.	435	7	
	AB	4,822,776	04/18/89	Cerami et al.	514	21	
	AC	5,658,570	08/19/97	Newman et al.	424	184.1	
	AD	5,750,105	5/12/98	Newman et al.	424	133.1	
	AE	5,231,024	7/27/93	Moeller et al.	435	240.27	
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI ON YES NO
KA	AL	0212489A2	04 MAR 87	EPO			
	AM	0218868A2	22 APR 87	EPO			
	AN	0288088A2	26 OCT 88	EPO			
	AO	0308378A2	22 MAR 89	EPO			
	AP	0380068A1	01 AUG 90	EPO			
	AQ	0393438A3	24 OCT 90	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KA	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985).
KA	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985).
KA	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985).

EXAMINER

Karen A. Gamella

DATE CONSIDERED

6/28/02

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 5, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
-------------------------------	--	-----------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL2	0398327A1	22 NOV 90	EPO			
KAC	AM2	0412486A1	13 FEB 91	EPO			
	AN2	0433900A1	26 JUN 91	EPO			
	AO2	0526905A2	10 FEB 93	EPO			
	AP2	WO91/02078	21 FEB 91	PCT			
✓	AQ2	WO92/07076	30 APR 92	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986).
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987).
	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987).
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987).
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987).
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).
✓	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).
KAC	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).


EXAMINER

Karen A. Gavella

DATE CONSIDERED

6/28/02

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-008		APPLICATION NO. 09/756,301			
INFORMATION DISCLOSURE IN AN APPLICATION July 5, 2001 (Use several sheets if necessary)		APPLICANT Junming Le, et al.					
		FILING DATE January 8, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL3	WO92/13095	06 AUG 92	PCT			
	AM3	0260610A2	23 MAR 88	EPO			
	AN3	91/09967	11 JUL 91	PCT			
	AO3	0351789A2	24 JAN 90	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).					
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).					
	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i> .					
	AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989).					
	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989).					
	AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989).					
	AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).					
EXAMINER		Karen A. Canella		DATE CONSIDERED		6/28/02	

		PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-008		APPLICATION NO. 09/756,301	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION FOR PATENT July 5, 2001 (Use several sheets if necessary)				APPLICANT Junming Le, et al.			
				FILING DATE January 8, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AP3	0350690A2	17 JAN 90	EPO			
	AQ3	90/00902	08 FEB 90	PCT			
	AL4	WO 92/11383	09 JUL92	PCT			
	AM4	WO 93/02108	4 FEB 93	PCT			
✓	AN4	WO 92/16553	19 MAR 92	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC	AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).					
	AS3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990).					
	AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990).					
	AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990).					
	AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990).					
	AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990).					
	AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990).					
✓	AY3	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990).					
EXAMINER <i>Karen A. Gancille</i>				DATE CONSIDERED 6/28/02			

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE
IN AN APPLICATION

July 5, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


KAC	AZ3	Nopfar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).
	AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).
	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).
	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).
	AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).
	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).
	AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).
	AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).
✓	AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).

EXAMINER

Karen A. Gancella

DATE CONSIDERED

6/28/02

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 0975.1005-008		APPLICATION NO. 09/756,301	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 5, 2001 (Use several sheets if necessary)				APPLICANT Junming Le, et al.			
				FILING DATE January 8, 2001		GROUP 1642	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
16AC	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991).					
	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).					
	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992).					
	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992).					
	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993).					
	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993).					
	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985).					
	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985).					
	AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990).					
✓	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991).					
EXAMINER <i>Karen A. Gamella</i>				DATE CONSIDERED 6/28/02			

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 5, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642

RECEIVED

JUL 11 2001

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, Endotoxemia & Sepsis Conference (1991).
KAC	AS6	Genebank Accession, No. N90300 (1989, November 1).
KAC	AT6	Genebank Accession, No. M32046 (1990, June 15).
KAC	AU6	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", Behring Inst. Mitt, No.78:118-132 (1985).

EXAMINER

Karen G. Gamella

DATE CONSIDERED

6/28/02

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

March 29, 2002

(Use several sheets if necessary)

APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIA TE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI ON YES NO
AO4	WO91/09967	11 JUL 91	PCT	dupl. cite		
KAL AP4	0486526B2	07 MAR 01	EPO			
KAL AQ4	WO92/02190	10 JUN 92	PCT			
AL5						
AM5						
AN5						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL AV6	Whittle, Nigel, et al., "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem</i> , Supl. 13A:96 (1989).
KAL AW6	Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem Immunol</i> , 2:457-466 (1990).
KAL AX6	Starnes, H. Fletcher, Jr., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J Immunol</i> , 145:4185-4191 (1990).

EXAMINER

Harun A. Gannella

DATE CONSIDERED

6/28/02

RECEIVED
APR 03 2002
TECH CENTER 1600/2900

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
0975.1005-008APPLICATION NO.
09/756,301APPLICANT
Junming Le, et al.FILING DATE
January 8, 2001GROUP
1642INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

APR 02 2002

March 29, 2002

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
-------------------------------	-----------------	------	------	-------	---------------	----------------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AY6	Duncombe, Andrew S. et al., "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J Immunol</i> , 143:3828-3834 (1989).
	AZ6	Aderka, Dan et al., "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J Immunol</i> , 143:3517-3523 (1989).
	AR7	Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," <i>Isr J Med Sci</i> , 27:52-60 (1991).
	AS7	Lassalle, Ph., et al., "Potential Implication of Endothelial Cells in Bronchial Asthma," <i>Int Arch Allergy Appl Immunol</i> , 94:233-238 (1991).
	AT7	Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin Immunol Immunopathol</i> , 55:157-170 (1990).
	AU7	Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor- α at 2.6 Å Resolution," <i>J Biol Chem</i> , 264:17595-17605 (1989).
	AV7	Gillies, Stephen D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J Immunol Methods</i> , 125:191-202 (1989).
✓	AW7	Kameyama, Koh-zoh, et al., "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett</i> , 244:301-306 (1989).

EXAMINER

Karen D. Gamella


DATE CONSIDERED

6/28/02

APR 03 2002

TECH CENTER 1600/2900

RECEIVED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 0975.1005-008		APPLICATION NO. 09/756,301			
		APPLICANT Junming Le, et al.					
		FILING DATE January 8, 2001		GROUP 1642			
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC	AX7	Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," Recent Adv. Chemother, 820-821 (1985).					
	AY7	Hirai, Makoto et al. "Production and characterization of monoclonal antibodies to human tumor necrosis factor," J Immunol Methods, 96:57-62 (1987).					
KAC	AZ7	Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor α and its antibodies using a bacterial cell wall carrier," J Immunol Methods, 109:203-214 (1988).					
EXAMINER		Karen A. Ganelle		DATE CONSIDERED		6/28/02	

RECEIVED
 APR 03 2002
 TECH CENTER 1600/2900